{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:05:53Z","timestamp":1789063553337,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"DOI":"10.1038\/s41416-026-03595-8","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:06:12Z","timestamp":1789059972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Programmed death ligand 1 (PD-L1) PET\/CT imaging to evaluate tumour saturation during atezolizumab treatment"],"prefix":"10.1038","author":[{"given":"Jahlisa S.","family":"Hooiveld-Noeken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim P.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kist de Ruijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris C.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia A. J.","family":"van Winkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danique","family":"Giesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn N.","family":"Lub-de Hooge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2698-1516","authenticated-orcid":false,"given":"Adrienne H.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2754-6997","authenticated-orcid":false,"given":"Sjoukje F.","family":"Oosting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike","family":"Bensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6010-8713","authenticated-orcid":false,"given":"Lotte M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien P.","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9142-9050","authenticated-orcid":false,"given":"Mathilde","family":"Jalving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd G.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0629-7354","authenticated-orcid":false,"given":"Jourik A.","family":"Gietema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regula J.","family":"Deurloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ungewickell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8306-6835","authenticated-orcid":false,"given":"Derk-Jan A.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8949-7425","authenticated-orcid":false,"given":"Elisabeth G. E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"3595_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"3595_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909\u201320.","journal-title":"Lancet"},{"key":"3595_CR3","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383:1328\u201339.","journal-title":"N Engl J Med"},{"key":"3595_CR4","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139.","journal-title":"N Engl J Med"},{"key":"3595_CR5","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395:1835\u201344.","journal-title":"Lancet"},{"key":"3595_CR6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"3595_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/19420862.2015.1136043","volume":"8","author":"R Deng","year":"2016","unstructured":"Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. mAbs. 2016;8:593\u2013603.","journal-title":"mAbs"},{"key":"3595_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.741855","volume":"8","author":"A Krache","year":"2022","unstructured":"Krache A, Fontan C, Pestourie C, Bardi\u00e8s M, Bouvet Y, Payoux P, et al. Preclinical pharmacokinetics and dosimetry of an 89Zr labelled anti-PDL1 in an orthotopic lung cancer murine model. Front Med. 2022;8:741855.","journal-title":"Front Med"},{"key":"3595_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.nucmedbio.2021.05.004","volume":"100-101","author":"A Bansal","year":"2021","unstructured":"Bansal A, Pandey MK, Barham W, Liu X, Harrington SM, Lucien F, et al. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. Nucl Med Biol. 2021;100-101:4\u201311.","journal-title":"Nucl Med Biol"},{"key":"3595_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1021\/acs.bioconjchem.7b00631","volume":"29","author":"C Truillet","year":"2017","unstructured":"Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, et al. Imaging PD-L1 expression with immunoPET. Bioconjug Chem. 2017;29:96\u2013103.","journal-title":"Bioconjug Chem"},{"key":"3595_CR11","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852\u20138.","journal-title":"Nat Med"},{"key":"3595_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"3595_CR13","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (NCI, 2009)."},{"key":"3595_CR14","doi-asserted-by":"crossref","unstructured":"Kaalep A, Huisman M, Sera T, Vugts D, Boellaard R, EARL; EATRIS; TRISTAN Consortium (#IB4SD-116106). Feasibility of PET\/CT system performance harmonisation for quantitative multicentre 89Zr studies. EJNMMI Phys. 2018;5:26.","DOI":"10.1186\/s40658-018-0226-7"},{"key":"3595_CR15","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2967\/jnumed.118.211607","volume":"59","author":"R Boellaard","year":"2018","unstructured":"Boellaard R. Quantitative oncology molecular analysis suite: ACCURATE. J Nucl Med. 2018;59:1753.","journal-title":"J Nucl Med"},{"key":"3595_CR16","unstructured":"Genentech: Tecentriq prescribing information. tecentriq_prescribing.pdf (gene.com)."},{"key":"3595_CR17","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.7150\/thno.15253","volume":"6","author":"M Hettich","year":"2016","unstructured":"Hettich M, Braun F, Bartholom\u00e4 MD, Schirmbeck R, Niedermann G. High-resolution PET imaging with therapeutic antibody-based PD-1\/PD-L1 checkpoint tracers. Theranostics. 2016;6:1629\u201340.","journal-title":"Theranostics"},{"key":"3595_CR18","first-page":"686","volume":"63","author":"J Smit","year":"2022","unstructured":"Smit J, Borm FJ, Niemeijer AN, Huisman MC, Hoekstra OS, Boellaard R, et al. PD-L1 PET\/CT Imaging with radiolabeled durvalumab in patients with advanced-stage non-small cell lung cancer. J Nucl Med. 2022;63:686\u201393.","journal-title":"J Nucl Med"},{"key":"3595_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.121.261926","volume":"63","author":"Niemeijer","year":"2022","unstructured":"Niemeijer, Oprea-Lager DE AN, Huisman MC, Hoekstra OS, Boellaard R, de Wit-van der Veen BJ, et al. Study of 89Zr-pembrolizumab PET\/CT in patients with advanced-stage non-small cell lung cancer. J Nucl Med. 2022;63:362\u20137.","journal-title":"J Nucl Med"},{"key":"3595_CR20","doi-asserted-by":"crossref","unstructured":"Gaykema SB, de Jong JR, Perik PJ, Brouwers AH, Schr\u00f6der CP, Oude Munnink TH, et al. 111In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment. Mol Imaging. 2014;13:1\u20136.","DOI":"10.2310\/7290.2014.00011"},{"key":"3595_CR21","doi-asserted-by":"publisher","first-page":"6128","DOI":"10.1158\/1078-0432.CCR-17-0311","volume":"23","author":"F Bensch","year":"2017","unstructured":"Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, et al. 89Zr-lumretuzumab PET Imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors. Clin Cancer Res. 2017;23:6128\u201337.","journal-title":"Clin Cancer Res"},{"key":"3595_CR22","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976\u201386.","journal-title":"N Engl J Med"},{"key":"3595_CR23","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/j.jtho.2019.05.026","volume":"14","author":"K Kunimasa","year":"2019","unstructured":"Kunimasa K, Nakamura H, Nishino K, Nakatsuka SI, Kumagai T. Extrinsic upregulation of PD-L1 induced by pembrolizumab combination therapy in patients with NSCLC with low tumor PD-L1 expression. J Thorac Oncol. 2019;14:e231\u20133.","journal-title":"J Thorac Oncol"},{"key":"3595_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","volume":"5","author":"LA Emens","year":"2019","unstructured":"Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study. JAMA Oncol. 2019;5:74\u201382.","journal-title":"JAMA Oncol"},{"key":"3595_CR25","doi-asserted-by":"publisher","first-page":"1078.","DOI":"10.1200\/JCO.2022.40.16_suppl.1078","volume":"40","author":"L Molinero","year":"2022","unstructured":"Molinero L, Emens LA, Goldstein LD, Abbas AR, Koeppen H, Rugo HS, et al. Mechanisms of action and acquired resistance to atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer (mTNBC). J Clin Oncol. 2022;40:1078.","journal-title":"J Clin Oncol"},{"key":"3595_CR26","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00280-019-03971-7","volume":"84","author":"DA Goldstein","year":"2019","unstructured":"Goldstein DA, Ratain MJ. Alternative dosing regimens for atezolizumab: right dose, wrong frequency. Cancer Chemother Pharmacol. 2019;84:1153\u20135.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3595_CR27","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1001\/jamaoncol.2022.4733","volume":"8","author":"C Kim","year":"2022","unstructured":"Kim C, Yang H, Kim I, Kang B, Kim H, Kim H, et al. Association of high levels of antidrug antibodies against atezolizumab with clinical outcomes and T-cell responses in patients with hepatocellular carcinoma. JAMA Oncol. 2022;8:1825\u20139.","journal-title":"JAMA Oncol"},{"key":"3595_CR28","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/psp4.13063","volume":"12","author":"S Marolleau","year":"2023","unstructured":"Marolleau S, Mogenet A, Boeri C, Hamimed M, Ciccolini J, Greillier L. Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients. CPT Pharmacomet Syst Pharmacol. 2023;12:1795\u2013803.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"3595_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280a (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558\u201362.","journal-title":"Nature"},{"key":"3595_CR30","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Braiteh FS, Loriot Y, Cruz C, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563\u20137.","journal-title":"Nature"},{"key":"3595_CR31","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/jcph.2203","volume":"63","author":"CJ Peer","year":"2023","unstructured":"Peer CJ, Schmidt KT, Arisa O, Richardson WJ, Paydary K, Goldstein DA, et al. In silico re-optimization of atezolizumab dosing using population pharmacokinetic simulation and exposure-response simulation. J Clin Pharmacol. 2023;63:672\u201380.","journal-title":"J Clin Pharmacol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03595-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03595-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03595-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:06:15Z","timestamp":1789059975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03595-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":31,"alternative-id":["3595"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03595-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Related to the subject, none. R.J. Deurloo, employee and shareholder of F. Hoffmann-La Roche Ltd., S.P. Williams, and A. Ungewickell are employees of Genentech Inc., a member of the Roche group, and stockholders of Genentech Inc.\/Roche. E.G.E. de Vries institutional financial support from Hoffman\u2013La Roche\/Genentech (payment to the institution). The other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Medical Ethical Committee of the UMCG and the Central Committee on Research Involving Human Subjects and registered individually. All patients provided written informed consent. This study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All patients provided written informed consent.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}